The Analyst Landscape: 27 Takes On Biogen
The Analyst Landscape: 27 Takes On Biogen
分析师格局：27人对Biogen的看法
In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，27位分析师发布了Biogen（纳斯达克股票代码：BIIB）的评级，提出了从看涨到看跌的各种观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要概述了他们最近的评级，重点介绍了过去30天中情绪的变化，并将其与前几个月进行了比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $280.81, a high estimate of $364.00, and a low estimate of $200.00. Experiencing a 3.19% decline, the current average is now lower than the previous average price target of $290.05.
分析师评估的12个月目标股价揭示了进一步的见解，平均目标价为280.81美元，最高估计为364.00美元，低估值为200.00美元。目前的平均价格下降了3.19％，现在低于之前的平均目标股价290.05美元。
Exploring Analyst Ratings: An In-Depth Overview
探索分析师评级：深入概述
The standing of Biogen...
通过对分...
登录免费看全文
登录/注册